Author

C. R. Goding

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. A. Ahmed· 1 shared A. C. Marques· 1 shared A. Coosemans· 1 shared A. Easton· 1 shared A. G. Smith· 1 shared A. L. Harris· 1 shared A. Lashgari· 1 shared A. R. Bassett· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Ahmed

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Systematic profiling of the acetyl lysine machinery reveals a role for MAPKAPK2 in bromodomain inhibitor resistance

P.-E. Kougnassoukou Tchara, J. Loehr, L. Germain, Z. Steinhart, B. Gonzalez-Badillo, A. Lashgari, F. J. M. Chartier, M. Tucholska, S. Picaud, J. D. R. Knight, S. Angers, N. Bisson, C. R. Goding, E. Audet-Walsh, P. Filippakopoulos, , J.-P. Lambert

This study maps the acetyl lysine machinery interactions and identifies MAPKAPK2 as a factor contributing to resistance to BET bromodomain inhibitors in melanoma.

bioRxiv · Jul 22, 2024 · PreprintCancer Biology

The lipid droplet protein DHRS3 is a regulator of melanoma cell state

E. Johns, Y. Ma, P. Louphrasitthipol, C. Peralta, M. V. Hunter, J. H. Raymond, H. Molina, C. R. Goding, R. M. White

The paper identifies DHRS3 as a lipid droplet protein that regulates melanoma cell state by modulating retinoid signaling.

bioRxiv · Mar 25, 2024Cancer Biology

LARP1 regulates metabolism and mTORC1 activity in cancer

J. Chettle, Z. Dedeic, R. Fischer, I. Vendrell, L. Campo, A. Easton, M. Browne, J. Morris, H. Schwenzer, P. Lascaux, R. Gijsbers, E. Pires, D. J. Royston, D. J. P. Ferguson, A. Coosemans, , S. P. Blagden

This study identifies LARP1 as a key regulator of metabolism and mTORC1 activity in cancer, showing its role in sustaining cellular metabolism and driving cancer progression.

bioRxiv · Sep 4, 2022 · PreprintCancer Biology

Phenotypic melanoma heterogeneity is regulated through cell-matrix interaction-dependent changes in tumor microarchitecture

L. Spoerri, C. A. Tonnessen-Murray, G. Gunasingh, D. S. Hill, K. A. Beaumont, R. J. Jurek, J. Chauhan, G. C. Vanwalleghem, M. E. Fane, S. M. Daignault-Mill, N. Matigian, G. M. Boyle, E. K. Scott, A. G. Smith, S. J. Stehbens, , N. K. Haass

This paper shows that melanoma phenotypic heterogeneity is controlled by cell-ECM crosstalk, altering tumor microarchitecture and mechanotransduction.

bioRxiv · Jun 9, 2020 · PreprintCancer Biology

The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor

E. A. Coe, J. Y. Tan, M. Shapiro, P. Louphrasitthiphol, A. R. Bassett, A. C. Marques, C. R. Goding, K. W. Vance

This study identifies DIRC3, a MITF-SOX10 regulated lncRNA, as a tumour suppressor in melanoma that promotes survival by modulating chromatin structure and IGFBP5 expression.

bioRxiv · Mar 27, 2019Cancer Biology